Patents by Inventor Guy R. Cornelis

Guy R. Cornelis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Virulence attenuated bacteria for treatment of malignant solid tumors
    Patent number: 11166987
    Abstract: The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains for use in a method of treating a malignant solid tumor in a subject.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: November 9, 2021
    Assignee: Universitaet Basel
    Inventors: Simon Ittig, Marlise Amstutz, Christoph Kasper, Guy R. Cornelis
  • Virulence Attenuated Bacteria For Treatment Of Malignant Solid Tumors
    Publication number: 20190015497
    Abstract: The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains for use in a method of treating a malignant solid tumor in a subject.
    Type: Application
    Filed: November 17, 2016
    Publication date: January 17, 2019
    Inventors: Simon Ittig, Marlise Amstutz, Christoph Kasper, Guy R. Cornelis
  • Tumor antigens and CTL clones isolated by a novel procedure
    Patent number: 7351409
    Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.
    Type: Grant
    Filed: January 7, 2004
    Date of Patent: April 1, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
  • Tumor antigens and CTL clones isolated by a novel procedure
    Publication number: 20040185033
    Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.
    Type: Application
    Filed: January 7, 2004
    Publication date: September 23, 2004
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
  • Tumor antigens and CTL clones isolated by a novel procedure
    Patent number: 6710172
    Abstract: The present invention relates to nucleic acid molecules encoding antigenic peptides from MAGE molecules that bind to HLA. An example of the nucleic acid molecules of the present invention is a nucleic acid molecule coding for the peptide GVYDGREHTV (SEQ ID NO: 44), which peptide binds to HLA-A2. The nucleic acid molecules and the encoded antigenic peptides are useful for diagnosing and treating various pathological conditions.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: March 23, 2004
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
  • Delivery of proteins into eukaryotic cells with recombinant Yersinia
    Patent number: 6602506
    Abstract: The present invention relates to recombinant Yersinia and the use thereof for delivery of proteins into eukaryotic cells, including related compositions and methods of treatment and related assays.
    Type: Grant
    Filed: May 25, 1999
    Date of Patent: August 5, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre B. van der Bruggen, Guy R. Cornelis, Anne M. Boland, Thierry R. Boon-Falleur
  • Delivery of proteins into eukaryotic cells with recombinant yersinia
    Patent number: 5965381
    Abstract: The present invention relates to recombinant Yersinia and the use thereof for delivery of proteins into eukaryotic cells, including related compositions and methods of treatment and related assays.
    Type: Grant
    Filed: March 6, 1998
    Date of Patent: October 12, 1999
    Assignees: Ludwig Institute for Cancer Research, Universite Catholique de Louvain
    Inventors: Pierre B. van der Bruggen, Guy R. Cornelis, Anne M. Boland, Thierry R. Boon-Falleur